Vertex Pharmaceuticals Inc / Ma VRTX

Revenue Intelligence Report • 53 quarters of SEC filing data • Updated 2026-03-06

Vertex Pharmaceuticals is experiencing significant revenue growth driven primarily by its strategic investments in SG&A, which yield a robust 2.48% increase in revenue for every 1% increase in spending. While R&D investments also contribute positively, their impact is more modest at 0.04% per 1% increase. Despite a recent holdout test indicating a substantial prediction error, the company is forecasting a strong FY revenue of $12 billion, reflecting a 55.2% year-over-year increase. This outlook suggests a promising return on investment for stakeholders as Vertex continues to capitalize on its operational efficiencies and market opportunities.

Next FY Revenue

$12.33B

+55.2% YoY

R&D Elasticity

0.04x

SG&A Elasticity

2.48x

Model Accuracy

16.8% MAPE

Holdout validation: The model predicted $3B vs the actual $2B — an error of 43.1%.

Investor insight: Actual revenue ($2B) came in 43% below the spending-based forecast ($3B). This suggests spending is not yet translating to revenue at historical rates.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q2 2022	$3B	$2B	$2B – $5B	+74.1%	✓ In range
Q3 2022	$3B		$1B – $5B	+54.6%
Q4 2022	$3B		$1B – $7B	+48.4%
Q1 2023	$3B		$1B – $8B	+53.4%
Q2 2023	$3B		$1B – $10B	+63.9%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch